Next 10 |
2024-04-12 17:05:37 ET Gainers: Applied Optoelectronics ( AAOI ) +5% . Eliem Therapeutics ( ELYM ) +4% . Infinera Corporation ( INFN ) +4% . Harrow ( HROW ) +4% . Health Catalyst ( HCAT ) +4% . Losers: Eagle Pharmaceutica...
2024-03-28 00:10:26 ET Summary Pyxis Oncology is developing antibodies and antibody-drug conjugates for various tumor types. Initial data from the phase 1 trials of PYX-106 and PYX-201 are now expected in H2'24 and fall 2024 respectively. PYXS raised $50M in gross proceeds wit...
2024-03-27 17:44:47 ET More on Pyxis Oncology Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis Pyxis Oncology gets $8M payment for sale of royalty rights Read the full article on Seeking Alpha For further details see: Pyxis...
2024-03-27 07:43:03 ET More on Pyxis Oncology Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis Pyxis Oncology stock rises as it looks to raise $50M through a private placement Seeking Alpha’s Quant Rating on Pyxis Oncology ...
Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen’s licensees discovered through the APXiMAB platform BOSTON, March 27, 2024 (GLOBE NEW...
2024-03-21 11:32:38 ET More on Pyxis Oncology Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis Pyxis Oncology stock rises as it looks to raise $50M through a private placement Read the full article on Seeking Alpha For further ...
2024-03-21 10:12:15 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Johnson & Johnson, Boston Scientific least shorted stocks in S&...
2024-03-21 08:43:23 ET Losers: Destination XL Group DXLG -16% after Q4 earnings release . Tourmaline Bio ( TRML ) -30% . Apyx Medical Corp APYX -17% after Q4 earnings release . Five Below FIVE -12% after Q4 earnings release . Designer Br...
PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private placement Expected cash runway into 2H 2026 BOSTON, March 21, 2024 (GLOBE NEWS...
2024-03-13 17:07:28 ET Gainers: Turtle Beach ( HEAR ) +22% . SoundHound ( SOUN ) +12% . Robinhood Markets ( HOOD ) +9% . Recursion Pharmaceuticals ( RXRX ) +7% . Pyxis Oncology ( PYXS ) +3% . Losers: WW International ( ...
News, Short Squeeze, Breakout and More Instantly...
Pyxis Oncology Inc. Company Name:
PYXS Stock Symbol:
NASDAQ Market:
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Re...
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. Shares of Signet Jewelers Limited (NYSE: SIG) rose sharply during ...
Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen’s licensees discovered through the APXiMAB platform BOSTON, March 27, 2024 (GLOBE NEW...